4-cycloakylaminopyrazolo pyrimidine NMDA/NR2B antagonists

US7452893B2 · kind B2 · utility

Assignee

• MERCK & CO., INC. · US

Inventors

• Wayne Thompson · Lansdale, US
• Steven D. Young · Lansdale, US
• Brian Phillips · Telford, US
• Peter M. Munson · Harleysville, US
• Willie Whitter · Johnstown, US
• Nigel J. Liverton · Harleysville, US
• Christine Dieckhaus · North Wales, US
• John W. Butcher · Telford, US
• John A. McCauley · Maple Glen, US
• Charles J. McIntyre · Lansdale, US
• Mark E. Layton · Harleysville, US
• Philip E. Sanderson · Philadelphia, US

Key dates

• Filing date: Aug 11, 2004
• Grant date: Nov 18, 2008
• Expiry date: Apr 5, 2025

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds represented by Formula (I) or pharmaceutically acceptable salts thereof, are effective as NMDA/NR2B antagonists useful for treating neurological conditions such as, for example, pain, Parkinson's disease, Alzheimer's disease, epilepsy, depression, anxiety, ischemic brain injury including stroke, and other conditions.